Early initiation of eculizumab treatment in patients with atypical haemolytic uraemic syndrome improves long-term outcomes: a pooled analysis of clinical trials

Lignende værker

• Progression to end-stage renal disease is reduced with eculizumab in patients with atypical haemolytic uraemic syndrome
  af: Walle, J Vande, et al.
  Udgivet: (2015)
• Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment
  af: Walle, Johan Vande, et al.
  Udgivet: (2016)
• Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study
  af: Menne, Jan, et al.
  Udgivet: (2018)
• Eculizumab in secondary atypical haemolytic uraemic syndrome
  af: Cavero, Teresa, et al.
  Udgivet: (2017)
• Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis
  af: Socié, Gérard, et al.
  Udgivet: (2019)